Cargando…
Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
INTRODUCTION: There is a pressing need to develop novel drugs for treating patients with chronic hepatitis B (CHB), as commercially available antiviral drugs are endowed with safety and efficacy concerns. METHODS: A phase III clinical trial was conducted with a therapeutic vaccine containing two ant...
Autores principales: | Al Mahtab, Mamun, Akbar, Sheikh Mohammad Fazle, Aguilar, Julio Cesar, Yoshida, Osamu, Khan, Sakirul, Gerardo, Guillen Nieto, Hiasa, Yoichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945514/ https://www.ncbi.nlm.nih.gov/pubmed/36844221 http://dx.doi.org/10.3389/fmed.2023.1032531 |
Ejemplares similares
-
Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021) -
Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022) -
Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
por: Al-Mahtab, Mamun, et al.
Publicado: (2023) -
The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021) -
Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)